Spruce Biosciences, Inc.
SPRB
$89.20
$6.097.33%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -90.18% | -86.43% | -71.27% | -51.32% | -1.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -90.18% | -86.43% | -71.27% | -51.32% | -1.40% |
| Cost of Revenue | 2.26% | -10.66% | -2.29% | -6.10% | -23.55% |
| Gross Profit | -24.92% | -11.04% | -16.14% | -5.50% | 27.54% |
| SG&A Expenses | -6.81% | -3.66% | 3.43% | 15.76% | 10.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.31% | -8.93% | -1.03% | -1.64% | -16.29% |
| Operating Income | -14.44% | -6.69% | -12.80% | -8.00% | 18.32% |
| Income Before Tax | -21.44% | -12.13% | -18.61% | -10.68% | 19.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.44% | -12.13% | -18.61% | -10.68% | 19.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.44% | -12.13% | -18.61% | -10.68% | 19.72% |
| EBIT | -14.44% | -6.69% | -12.80% | -8.00% | 18.32% |
| EBITDA | -14.53% | -6.75% | -12.87% | -8.05% | 18.30% |
| EPS Basic | -17.55% | -8.59% | -15.15% | -1.50% | 35.74% |
| Normalized Basic EPS | -17.55% | -8.59% | -15.15% | -1.50% | 35.74% |
| EPS Diluted | -17.55% | -8.59% | -15.15% | -1.50% | 35.74% |
| Normalized Diluted EPS | -17.55% | -8.59% | -15.15% | -1.50% | 35.74% |
| Average Basic Shares Outstanding | 4.67% | 4.47% | 2.92% | 7.22% | 20.20% |
| Average Diluted Shares Outstanding | 4.67% | 4.47% | 2.92% | 7.22% | 20.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |